Kilpatrick Townsend’s Silicon Valley-based start-up team advised the founders of Editas Medicine in the biotech start-up’s $43 million Series A Financing. In a trend setting transaction, venture firms Polaris Partners, Third Rock Ventures, Flagship Ventures and the Partners Innovation Fund invited five of the most prominent research scientists in the field of genomics from MIT, Harvard, the Howard Hughes Medical Institute and the University of California in Berkeley to form a company which they would fund. The money invested will fund the collaborative research and development by this world-class team of scientists as they seek to revolutionize the treatment of genetic disorders by developing a simple, precise and inexpensive method of ‘editing out’ abnormalities in genes in human cells.

Experience Center

Match our Experience to Your Needs

View All Case Studies

Experience Highlights

Arbitration for a global supplier of electro-mechanical equipment, systems, and services
The firm served as lead counsel to a global supplier of electro-mechanical equipment, systems, and services in an arbitration where the owner alleged more
Environmental class action litigation for farmers and an agricultural association
Represented commercial seed farmers and their agricultural trade association who were sued in Idaho state court in a nuisance and trespass class more
Patent prosecution and counseling for Inserm
Provided patent prosecution advice to Inserm (Institut national de la santé et de la recherché médicale). Inserm is the only French public more
Patent prosecution and counseling for Children's Medical Center Corporation
Represents Children’s Medical Center Corporation, which is affiliated with Harvard University, and have prepared and prosecuted to issuance numerous more